CJC-1295 (without DAC) vs HGH Fragment 176-191
Well Studied vs Moderate Research
monitor Mechanism-based · 47% Both CJC-1295 (without DAC) and HGH Fragment 176-191 affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
CJC-1295 (without DAC) HGH Fragment 176-191
Weight 3,367.97 Da 1,817.1 Da
Half-life 30 minutes - 2 hours 15-20 minutes
Chain 30 amino acids 16 amino acids
Type GHRH analog hGH C-terminal fragment (176-191)
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
HGH Fragment 176-191
01 Stimulates lipolysis without growth hormone side effects
02 Does not affect blood glucose or insulin sensitivity
03 Does not increase IGF-1 levels
04 Selectively targets fat metabolism
05 No impact on bone or organ growth
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
HGH Fragment 176-191
250-500mcg / Twice daily (fasted)
Fat loss - Standard 250mcg Twice daily (morning fasted + pre-bed)
Enhanced fat loss 500mcg Twice daily (morning fasted + pre-bed)
Conservative start 250mcg Once daily (morning, fasted)
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
HGH Fragment 176-191
Injection site irritation (redness, mild swelling)
Headache, particularly in the first few days
Generally well-tolerated with a favorable safety profile
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Active cancer or history of malignancy
WADA prohibited - athletes subject to testing must avoid
Research Evidence
CJC-1295 (without DAC) HGH Fragment 176-191
Status Well Studied Moderate Research
References 5 studies 4 studies
Latest November 2024 2014
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.